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Abstract
Background The Stop&Go study randomized patients with advanced breast cancer to intermittent (two times four) or con-
tinuous (eight subsequent cycles) first- and second-line chemotherapy.
Methods QoL was measured with RAND-36 questionnaires every 12 weeks. The primary objective was to estimate dif-
ferences in changes from baseline between intermittent and continuous treatment. An effect size of 0.5 SD (5 points) was 
considered clinically meaningful.
Results A total of 398 patients were included with a median follow-up of 11.4 months (IQR 5.6–22.2). Mean physical QoL 
baseline scores were 38.0 resp. 38.2, and mental scores 45.0 resp. 42.4 for intermittent and continuous treatment. Physi-
cal QoL declined linearly in the intermittent arm causing a clinically meaningful difference of 5.40 points at 24 months 
(p < 0.001), while scores in the continuous arm stabilized after a small decline of ± 3.4 points at 12 months. Conversely, 
mental QoL was fairly stable and even improved with 1.58 (p = 0.005) and 2.48 points (p < 0.001) at 12 months for inter-
mittent and continuous treatment, respectively. When comparing arms for both components in changes from baseline, the 
maximum differences were 2.46 (p = 0.101) and 1.95 points (p = 0.182) for physical and mental scores, both measured at 
30 months and in favor of continuous treatment.
Conclusion Intermittent first- and second-line chemotherapy in patients with HER2-negative advanced breast cancer showed 
a trend for worse impact on QoL compared to continuous chemotherapy, with neither significant nor meaningful differences 
in course. We recommend prescribing chemotherapy continuously until progressive disease or unacceptable toxicity.
Trial registration EudraCT 2010-021519-18; BOOG 2010-02
Keywords Quality of life · Advanced breast cancer · Chemotherapy · Scheduling
Introduction
Breast cancer is the most common cancer among women 
worldwide [3]. Approximately 20–30% of all breast can-
cer patients will eventually develop metastases [4]. While 
the 5-year survival rate for women with breast cancer of all 
stages is estimated at 82%, survival rates for advanced breast 
cancer are relatively poor [5, 6]. Patients with advanced 
breast cancer (defined here as incurable locally advanced or 
metastatic breast cancer) experience a significant burden of 
disease [7]. The treatment goals for these patients are there-
fore to prolong survival and preserve Quality of life (QoL). 
The experienced QoL is determined by both tumor related 
complaints as well as the side effects of treatment. Different 
treatment strategies may improve survival and QoL, or keep 
either survival or QoL constant, while improving the other. 
It is also possible that QoL is improved, while survival is 
slightly reduced, or the other way around.
The Stop&Go study was a non-inferiority trial randomiz-
ing patients with advanced breast cancer to two sets of four 
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cycles (intermittent) or eight consecutive cycles (continu-
ous) of chemotherapy in first- and second-line treatment [8]. 
The hypothesis was that the intermittent treatment would 
improve QoL. Recently, we reported the first efficacy results 
from the Stop&Go trial, showing a lack of non-inferiority in 
progression-free survival (PFS) (medians 7.4 vs. 9.7 months, 
Hazard ratio [HR] 1.17; 95% CI 0.88–1.57), and shorter 
overall survival (OS) (medians 17.5 vs. 20.9 months, HR 
1.38; 95% CI 1.00–1.91) for the experimental intermittent 
arm compared to the continuous arm in first-line treatment. 
[8] Here we report on the prospectively planned QoL analy-
ses. If QoL is indeed better in the experimental arm, patients 
and physicians could make a trade-off between better QoL 
and better survival.
Methods
Study design and treatment
An extensive description of the study design has been 
published previously [8]. In brief, the Stop&Go study is a 
phase III trial assessing the impact of scheduling of first- and 
second-line chemotherapy in patients with HER2-negative 
advanced breast cancer. Participants were randomized to 
two sets of four cycles (intermittent) or eight consecutive 
cycles (continuous) of chemotherapy in first- and second-
line treatment. First-line treatment consisted of paclitaxel 
plus bevacizumab, second-line treatment of capecitabine or 
non-pegylated liposomal doxorubicin.
QoL assessments
QoL was measured by RAND-36 questionnaires [9], which 
were distributed by post at baseline and every 12 weeks dur-
ing study treatment and follow-up until death or withdrawal 
due to any reason. Information about the social status of 
patient at randomization was collected retrospectively.
The questionnaire contains 36 multiple choice items 
divided over 8 subscales and is almost identical to the SF-36 
[9, 10]. We first calculated the 8 subscales of the RAND-
36 using the Dutch algorithm [11]. The weights of this 
algorithm to calculate T-scores (mean = 50, SD = 10) were 
obtained in several large Dutch samples (total n = 6822). As 
there is no Dutch algorithm for the calculation of physical 
and mental components of QoL out of the RAND-36, we 
then applied US weights used for the SF-36 to determine 
these component scores [12]. The physical and mental com-
ponent scores are presented as T-scores with a mean of 50 
and a standard deviation (SD) of 10 for the normal popula-
tion, with higher scores representing better QoL. Individual 
missing items of the RAND-36 were handled using the algo-
rithm presented by Ware [13].
Outcomes
The evaluation of QoL comprised a secondary objec-
tive of the Stop &Go study. The primary, prospectively 
planned, objective was to describe the course of physi-
cal and mental QoL for both treatment arms, and to esti-
mate differences in changes from baseline in physical and 
mental QoL between arms. Secondary objectives, added 
post hoc, were to assess the influence of age, Body Mass 
Index (BMI), living alone, Eastern Cooperative Oncol-
ogy Group Performance Status (ECOG PS) at baseline, 
disease-free interval (DFI) between initial diagnosis and 
metastatic diagnosis, site of metastasis at baseline, receiv-
ing prior hormonal therapy for advanced disease, number 
and duration of (re-) hospitalizations, duration of first-line 
treatment, and receiving first- and/or second-line study 
treatment on QoL and compare these influences between 
treatment arms.
Statistical analyses
QoL analyses included all patients within the Stop&Go 
study who responded to at least one questionnaire with suf-
ficient valid data, according to the intention-to-treat prin-
ciple. Baseline differences between study arms, dropouts 
and participants were analyzed with χ2 tests with continu-
ity correction, t tests or Mann–Whitney U tests.
Differences in changes from baseline were estimated 
longitudinally with multilevel linear regression analy-
ses. These analyses can handle data with unbalanced and 
incomplete time points, assuming missing at random, 
efficiently. For this multilevel approach, three levels were 
included; institute as upper level, the patients as middle 
level and their repeated measures as lower level. The devi-
ance test was applied to determine the necessity of the 
institute level [14, 15]. For analyses of the treatment effect 
only, the fixed parts of the models included time, the loga-
rithm of time, treatment group, and the interactions. For 
the secondary analyses of the covariate effects, separate 
models were postulated including these covariates with 
first- and second order interactions.
In order to prevent the few cases with very long follow-
up measures to exert an unduly great influence on the mod-
els, we determined the 90th percentile of the maximum 
follow-up time per case. Analyses were performed within 
the period until this 90th percentile.
For the primary analyses a Bonferroni correction was 
applied and p values < 0.025 were considered significant. 
For the exploratory secondary analyses p values < 0.05 
were maintained. Based on a systematic review about 
minimally important differences in health-related QoL 
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studies, an effect size of 0.5 SD (in this case 5 points on 
the component scores) was considered clinically meaning-
ful [16]. Additionally, we considered a change of 2 points 
on the component scores a small effect, 5 points a medium 
effect and 8 points a large effect. [17].
Post hoc power analyses estimated the minimum detect-
able effect size. We used the observed correlations between 
the measurements, an alpha of 0.025 and a power of 0.80. As 
the number of measurements declined rather fast, for each 
outcome two power analyses were performed: one based on 
two measurement points and one on four.
Statistical analyses were performed with IBM-SPSS ver-
sion 24.
Results
Patient and treatment characteristics
At the time of data cut-off for the current analyses (May 1, 
2018) a total of 420 patients were included and randomized 
in the Stop&Go study, of whom 402 (96%) responded to the 
QoL baseline questionnaire. Due to too much missing items 
or questionnaires, the population for analyses included 198 
patients in the intermittent, and 200 patients in the continu-
ous arm with at least one valid RAND-36 administration 
(total n = 398) (Fig. 1). There were no statistical significant 
differences in any of the patient- or treatment characteristics 
between the arms except for the DFI, which was longer for 
the intermittent treatment arm (Table 1). No significant dif-
ference was found in proportion of patients who continued 
on second-line treatment (Table 1, Fig. 1). Additionally, no 
significant differences were observed between the 22 non-
responders compared to the 398 responders in treatment 
arm, early death, age and BMI (data not shown).
Points of assessment
The maximum follow-up time was 68.2 months, with a 
median of 11.4 months (IQR 5.6–22.2). Median number of 
questionnaires per patient was 4.3 (IQR 2.1–7.5). Consid-
ering that 90% of the patients had a follow-up time within 
the range of 0.0 to 30.6 months, we limited the analyses to 
30.6 months (Fig. 1, Supplementary Fig. S1). Drop-out of 
QoL assessments should take into account that active par-
ticipants should administer a questionnaire every 12 weeks 
and may be overdue for half of that period. Thus at the end 
of the first year, participants should have responded after 
34 weeks, or in case they deceased, should have responded 
at least 18 weeks before they died. At 12 months 297 women 
were still alive (75%), and 101 (25%) had deceased. Of 
the alive patients, 56 (19%) dropped out due to unknown 
reasons, while 21 of the deceased patients (21%) did not 
administer a questionnaire in their last 18 weeks of life, indi-
cating reasons for drop-out other than death. At 24 months, 
180 women were still alive (45%) and 218 had deceased 
(55%). A total of 76 alive participants (42%) dropped out, 
and 68 of the deceased (31%) dropped out at least 18 weeks 
prior to death. At the end of the study period at 30 months, 
145 women were still alive (36%), and 253 had died (64%). 
Eighty-seven patients alive dropped out (60%) and 86 of the 
deceased patients (34%) dropped out prior to death.
Changes in QoL over time
The deviance test pointed out that the institute level was 
superfluous (χ2(1) = 2.22, p = 0.136). The estimates of the 
physical and mental component model for the main treat-
ment effect without covariates at the various time points 
are presented in Table 2. Mean baseline scores were 38.0 
and 38.2 for physical, and 45.0 and 42.4 for mental QoL 
with intermittent and continuous treatment, respectively. The 
model itself is presented in Supplementary Table S1.
In the intermittent arm there was an almost linear decline 
of physical QoL causing a clinically meaningful difference 
of 5.40 points at 24 months (p < 0.001), while scores in the 
continuous arm stabilized after a decline of ± 3.4 points 
at 12 months (Table 2, Fig. 2a). Considering mental QoL 
(Table 2, Fig. 2b), a lower baseline score was observed 
in the continuous arm (± 2.5 points, p = 0.021) compared 
to the intermittent arm. Both arms showed an increase in 
mental health after start of the study treatment (1.58 points; 
p = 0.005 and 2.48 points; p < 0.001 at 12 months for inter-
mittent and continuous treatment). Similar to the course of 
physical QoL, the continuous arm had slightly more stable 
mental QoL scores than the intermittent arm, although for 
both arms there were no clinically meaningful changes com-
pared to baseline.
When comparing the arms for both components in 
changes from baseline, the maximum differences were 2.46 
points (p = 0.101) for physical and 1.95 points (p = 0.182) 
for mental scores, both measured at 30 months and in favor 
of continuous treatment.
Secondary analyses
Age and BMI had no significantly differential effect on the 
course of both physical and mental QoL from baseline for 
the two treatment arms. Duration of first-line treatment 
did not affect physical and mental QoL scores over time. 
Regarding the social status of the patients, there were no 
significant differences between patients that lived alone 
and those living together for both physical and mental 
QoL. Likewise, the duration and number of (re)hospitali-
zations and the treatment line had no effect on both the 
physical and mental QoL scores over time. The 23 patients 
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Fig. 1  Flowchart of QoL response rates. The blue bars represent QoL measurements during first-line study treatment, the green bars represent 
QoL measurements during second-line study treatment, and the yellow bars represent QoL measurements during follow-up
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with a baseline ECOG PS score of 2 had 13.1-point lower 
baseline scores on the physical component (p < 0.001) 
compared to patients with better performance status. These 
scores increased slightly until 6.8 months, where after 
there was a large decrease. No significant differences in 
physical QoL between the treatment arms were observed 
within this group compared to patients with better per-
formance status (data not shown). Regarding the mental 
component score, no significant differences were found at 
all. Concerning the influence of DFI between initial and 
metastatic diagnosis, patients within the continuous arm 
had a 0.04 point lower physical component baseline score 
for each additional month between the initial and meta-
static diagnosis (p = 0.007). No further differences were 
found. For the mental score no relevant significant differ-
ences were observed.
Discussion
In this study we found no significant differences between 
intermittent and continuous first- and second-line chemo-
therapy for changes from baseline of both physical and 
mental QoL in patients with HER2-negative advanced 
breast cancer. Interestingly, when looking at the physi-
cal QoL scores in the treatment arms separately, the total 
decline was considered a clinically meaningful medium 
effect in the intermittent arm (decline > 5 points on the 
Table 1  (A) Baseline and (B) treatment characteristics in intermittent and continuous arms (ITT population, n= 398)
ITT, intention to treat; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ER, estrogen receptor; 
PgR, progesterone receptor; DFI, disease-free interval, IQR, inter quartile range; χ2, chi square; df, degrees of freedom, M–W Z, Mann–Whit-
ney Z
Italic p values are considered statistically significant
a Missing ECOG PS: n = 1 vs. for intermittent arm
(A) Baseline characteristics
Intermittent (n = 198) Continuous (n = 200) Total (n = 398)
Mean age in years (± SD) 58.2 (8.6) 59.0 (10.1) 58.6 (9.4)
Mean BMI (± SD) 26.1 (4.9) 26.3 (5.0) 26.2 (5.0)
Mean follow-up time in months (± SD) 13.3 (9.5) 13.4 (9.2) 13.3 (9.3)
Cohabited (%) 91/115 (79.1%) 101/129 (78.3%) 192/244 (78.7%)
ECOG  PSa
 0–1 189/197 (95.9%) 186/200 (93.0%) 375/397 (94.5%)
 2 8/197 (4.1%) 14/200 (7.0%) 22/397 (5.5%)
Site of metastatic disease
 Visceral 20 (10.1%) 18 (9.0%) 38 (9.5%)
 Non-visceral 29 (14.6%) 25 (12.5%) 54 (13.6%)
 Visceral and non-visceral 149 (75.3%) 157 (78.5%) 306 (76.9%)
Prior hormonal therapy for metastatic disease 94 (47.5%) 89 (44.5%) 183 (46.0%)
Intermittent Continuous M–W Z p value
Median DFI (months) between initial diagno-
sis and metastatic diagnosis [IQR]
55.0 [23.4–88.8] 39.1 [18.5–86.9] − 1.592 0.111
(B) Treatment characteristics
Intermittent Continuous χ2(df) p value
No. of patients with first-line treatment only 
(%)
71 (35.9%) 67 (33.5%) 0.151(1) 0.697
No. of patients with second-line treatment (%) 127 (64.1%) 133 (66.5%)
M–W Z p value
Median duration (months) until end of first-
line treatment [IQR]
6.1 [4.4–12.5] 8.7 [5.3–11.4] − 1.517 0.129
Median duration (months) until start second-
line treatment [IQR]
7.8 [5.7–13.7] 10.5 [7.8–13.4] − 2.017 0.044
Median total duration (months) of (re)hospi-
talizations [IQR]
3.0 [0.0–11.2] 4.3 [0.0–12.0] − 0.773 0.439
Median number of (re)hospitalizations [IQR] 0.2 [0.0–1.4] 0.3 [0.00–1.4] − 0.103 0.918
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component score) and a small, clinically not meaningful 
(< 5 points) effect in the continuous arm (Table 2, Fig. 2).
Although the differences in course of QoL scores 
between treatment arms in our current study are not sta-
tistically significant nor clinically meaningful, a trend for 
worse scores on the long term can be observed to the det-
riment of intermittent treatment (Table 2). However, the 
number of patients still responding to questionnaires at 
30 months is small (n = 48), which limits the clinical sig-
nificance due to selection of patients with more favorable 
prognosis (Figs. 1, 2). Nevertheless, the observed trend 
accompanies our previous observation based on efficacy 
results in a consistent manner, underlining the conclusion 
that continuous treatment was more effective in prolonging 
survival and did not compromise QoL.
Mental component scores were generally better than 
physical component scores for both arms. There was even 
a slight increase in mental QoL for both treatment arms 
after the start of study treatment (Table 2, Fig. 2b). Specu-
latively this might be due to a drop in mental QoL before 
the study, when the patients received their metastatic breast 
cancer diagnosis. Psychological coping with this new pros-
pect results in a return to the pre-diagnosis mental state. A 
similar phenomenon, a temporal drop in mental QoL after a 
severe diagnosis, has been observed in other studies [18–21].
Our observation that continuous scheduling of chemo-
therapy for patients with advanced breast cancer did not 
jeopardize QoL—in contrast to shorter interrupted chem-
otherapy schedules—has equivalents in literature. Five 
[22–26] out of six [27] randomized controlled trials on 
longer versus shorter successive durations of chemotherapy 
for advanced breast cancer measuring QoL found compara-
ble or better QoL with longer durations of chemotherapy. 
The study of Coates and colleagues resembles our study 
best [25]. There, patients were randomized to three cycles 
of chemotherapy intermittently, versus continuous chemo-
therapy, both until disease progression occurred. Although 
the outdated chemotherapy regimen used in that study limits 
its relevance today, Coates also found worse QoL scores for 
intermittent compared to continuous treatment [25].
Strengths of this study include the evaluation of QoL 
alongside efficacy endpoints, something often neglected 
by investigators within this particular field [28]. Stud-
ies that do not include QoL analyses can be considered 
to have an important shortcoming, as outcomes relevant 
for the patients are missing. Oncologic studies that do 
include QoL outcomes mostly use standardized question-
naires (e.g., QLQ-C30, QLQ-BR23 and FACT-B) that also 
focus on disease-specific symptoms, e.g., for breast cancer 
patients related to local breast surgery, body image and 
sexual functioning [28]. In comparison, the RAND-36 
used here may be too generic to detect subtle differences 
between the two treatment groups. On the other hand, one 
can expect more general effects of intermittent therapy on 
the QoL than just the local, disease-specific symptoms. 
Indeed, the idea was that intermittent therapy should have 
a positive effect on work- and other daily activities, espe-
cially in the earlier lines of chemotherapy. We therefore 
chose to involve a generic questionnaire, which measures 
QoL from a broad perspective, at the risk of missing the 
influence of important facets such as neuropathy [29]. 
Additionally, the RAND-36 is relatively short and has high 
interval validity and sensitivity to fluctuations in general 
health. It is widely used, and therefore the results are com-
parable with many other studies [10].
Although our trial was not powered to proof signifi-
cant differences in the secondary endpoints (including 
predefined QoL outcomes), post-hoc power calculations 
revealed that the differential effects that could have sig-
nificantly been found, were smaller than the ‘minimal 
important difference’ of ± 0.5 SD reported in literature on 
Table 2  Estimated physical and mental components of QoL scores
Intermittent Continuous
Months 0 12 24 30 0 12 24 30
Physical component 37.96 35.13 32.57 31.30 38.17 34.78 34.14 33.97
 Difference with baseline 0.00 − 2.84 − 5.40 − 6.66 0.00 − 3.39 − 4.04 − 4.20
 p value 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
 Difference continuous–intermittent 0.00 0.55 − 1.36 − 2.46
 p value 0.542 0.265 0.101
Mental component 44.95 46.53 44.90 43.89 42.43 44.91 43.99 43.33
 Difference with baseline 0.00 1.58 − 0.05 − 1.06 0.00 2.48 1.55 0.89
 p value 0.005 0.601 0.856 < 0.001 0.002 0.024
 Difference continuous–intermittent 0.00 − 0.89 − 1.60 − 1.95
 p value − 0.083 − 0.150 − 0.182
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QoL research [16]. For the physical component, a differ-
ential effect of 0.301 SD between the treatment arms could 
have been found applying two measurement points, and an 
effect of 0.301 SD applying four measurement points. For 
the mental component, these effects were 0.327 SD and 
0.333 SD, respectively. Therefore, our interpretation of the 
outcome of the study is not hampered by a lack of power.
In conclusion, intermittent chemotherapy showed a trend 
for worse impact on QoL compared to continuous chemo-
therapy in advanced breast cancer. In combination with the 
previously reported reduced efficacy, we therefore do not 
recommend this strategy in first- and second-line chemother-
apy for patients with HER2-negative advanced breast cancer.
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Fig. 2  Course of the physical (a) and mental (b) components of the 
RAND-36 for both treatment groups. The red dotted lines represent 
intermittent treatment. The blue lines represent continuous treatment. 
Bold lines represent the estimates. The dotted light lines represent 
a difference of 5 points with the baseline score for both intermittent 
treatment (red) and continuous treatment (blue), which are considered 
to be clinically meaningful. The T-scale on the Y-axis is stretched. 
The T-scale has a mean on average of 50, and a SD of 10. Higher 
scores indicate better QoL
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